Crossmark

The differences between insulin glargine U300 and insulin degludec U100 in impact on the glycaemic variability, arterial stiffness and the lipid profiles in insulin naïve patients suffering from type two diabetes mellitus – outcomes from cross‐over open-label randomized trial

Crossref DOI link: https://doi.org/10.1186/s12902-021-00746-1

Published Online: 2021-04-29

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cindro, Pavle Vrebalov

Krnić, Mladen

Modun, Darko

Smajić, Božo

Vuković, Jonatan
License Information

Text and Data Mining valid from 2021-04-29

Version of Record valid from 2021-04-29
More Information

Article History

Received: 18 January 2021

Accepted: 12 April 2021

First Online: 29 April 2021

Declarations

:

: This randomized, open-label, crossover study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the University of Split School of Medicine (number 2181-198-03-04-17-0045). All subjects gave written consent prior to their participation in the study.

: Not applicable.

: M.K. received honoraria from Sanofi, NovoNordisk, Elly Lilly, Abbott, MSD, Takeda, Novartis, Boehringer Ingelheim, Servier, Lifescan and Astra Zeneca as a speaker and for attendance at advisory boards. Author does not have any conflict of interests associated with this research.P.V.C. received honoraria from Abbot, Teva and Takeda as a speaker and a case presenter. Author has no conflict of interests associated with this research.J.V., B.S. and M.D. declare no conflict of interests associated with this research.

Document is current

Any future updates will be listed below